Reviews/P2Y12 Antiplatelets/Cangrelor improves outcomes vs oral P2Y12 in cardiogenic shock PCI
Cangrelor · P2Y12-CANG-02 · v2
Only one study in this corpus directly compares cangrelor with oral P2Y12 inhibitors in cardiogenic shock patients undergoing PCI [8], and it was a retrospective matched-pair analysis of 88 pairs rather than a randomized trial. In that study cangrelor-treated patients had lower death rates at 30 days and 12 months, but neither difference reached statistical significance (P=0.34 and P=0.08); the only statistically significant benefit was better TIMI blood-flow during the procedure, an angiographic measure rather than a hard clinical outcome. Randomized trials of cangrelor exist, but in general PCI [3] and acute coronary syndromes [12], not in shock, and they point in different directions. Other shock data [9], [10] are single-arm series with no comparator, and [11] shows the oral comparator drugs are themselves effective in shock. The panel therefore read the signal as favorable in direction but unproven on clinical outcomes in this population.
The corpus contains one direct comparison in cardiogenic shock PCI [8], where 30-day and 12-month mortality were 29.5% and 34.1% with cangrelor versus 36.4% and 47.1% with oral P2Y12 (P=0.34 and P=0.08), with significantly more patients achieving at least one TIMI flow grade improvement (92.9% vs 81.2%, P=0.02) and similar bleeding (21.6% vs 19.3%, P=0.71). Randomized evidence of cangrelor versus clopidogrel is favorable in general urgent or elective PCI [3] (4.7% vs 5.9%, OR 0.78, P=0.005) but non-superior in ACS [12] (7.5% vs 7.1%, OR 1.05, P=0.59), and neither enrolled shock patients. In the same shock population, potent oral P2Y12 inhibitors reduced MACE versus clopidogrel [11] (16.6% vs 24.7%, HR 0.76, P=0.046). Uncontrolled cangrelor series in shock [9] (n=17) and [10] (n=411) describe feasibility and safety only. The contested point: The division is between a favorable mortality direction in the single shock comparison [8] and the fact that this difference was not statistically significant, leaving procedural TIMI flow as the only significant finding. Whether a surrogate improvement plus non-shock randomized support [3], offset by a non-superior ACS trial [12], can sustain a claim of improved clinical outcomes is the unresolved point.
All 19 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from P2Y12 Antiplatelets, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The only paper directly comparing cangrelor with oral P2Y12 in cardiogenic shock [8] is a retrospective 1:1 matched-pair analysis (88 pairs), not randomised — residual confounding and treatment-selection bias are likely, and 30-day and 12-month mortality differences were NOT statistically significant (P=0.34 and P=0.08).
The single significant efficacy result in [8] is TIMI flow grade improvement (92.9% vs 81.2%, P=0.02) — a periprocedural angiographic surrogate. Equating a surrogate with 'improves outcomes' is overreach from the claim's exact wording.
Where it remains uncertain. Randomized support comes from non-shock populations that disagree — favorable in general PCI [3] but non-superior in ACS [12] — while the oral comparator is itself effective in shock [11].
Aleatory
The only direct comparison [8] rests on 88 matched pairs, so mortality estimates carry wide sampling variability and the non-significant P values (0.34, 0.08) may reflect limited power.
Epistemic
No completed randomized comparison of cangrelor versus oral P2Y12 in cardiogenic shock exists in the corpus; [8] itself calls for randomized evaluation.
Inferential
Benefit is inferred from general PCI [3] and ACS [12] randomized data, but these enrolled no shock patients and disagree in direction.
The load-bearing papers from a corpus of 19, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Indirect support: cangrelor reduces ischaemic events vs oral clopidogrel in general urgent/elective PCI (not CS).
“The rate of the primary efficacy end point was 4.7% in the cangrelor group and 5.9% in the clopidogrel group (adjusted odds ratio with cangrelor, 0.78; 95% confidence interval [CI], 0.66 to 0.93; P=0.005).”
Panel auditInternal validity: high · scope of inference: Effect of cangrelor versus clopidogrel on periprocedural ischemic events in patients undergoing urgent or elective PCI generally.Key limitations: cardiogenic shock not reported · population broader than the claim
Direct cangrelor-vs-oral-P2Y12 comparison in CS; favorable mortality direction but non-significant at both timepoints.
“The use of cangrelor in CS offers a potentially safe and effective antiplatelet option and should be evaluated in randomized trials.”
Panel auditInternal validity: low · scope of inference: Clinical course of cardiogenic shock PCI patients treated with cangrelor versus matched oral P2Y12-treated controls over 12 months.Key limitations: retrospective matched pairs · underpowered for clinical outcomes · only TIMI flow surrogate reached significance
Shows the oral-P2Y12 comparator is heterogeneous and itself reduces MACE in AMI+CS, qualifying any blanket 'improves vs oral P2Y12' claim.
“The risk of MACE was significantly lower in the potent P2Y12 inhibitors group than in the clopidogrel group (16.6% versus 24.7%; adjusted hazard ratio [HR], 0.76 [95% CI 0.59-0.99]; P = 0.046).”
Panel auditInternal validity: medium · scope of inference: Oral potent P2Y12 versus clopidogrel in AMI complicated by cardiogenic shock undergoing PCI.Key limitations: no cangrelor · observational registry · oral vs oral only
Uncontrolled feasibility/safety signal for cangrelor in CS/MCS; no comparator, cannot establish superiority.
“No patient developed in-stent thrombosis during the hospitalization; 14 (82%) patients survived their MCS course.”
Panel auditInternal validity: low · scope of inference: Bleeding complications and dosing of cangrelor in cardiogenic shock PCI patients on mechanical circulatory support.Key limitations: case series n=17 · no comparator · descriptive only
4 of 19 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A favorable but statistically non-significant retrospective signal plus surrogate-only significance and non-CS RCT support do not carry a claim of improved clinical outcomes.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No randomized shock comparison. The only direct evidence [8] is retrospective and non-significant on mortality, leaving superiority on hard outcomes unestablished in shock. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomized trial of cangrelor versus a prespecified oral P2Y12 inhibitor in cardiogenic shock PCI, powered for 30-day and 12-month mortality.
Open question: Does cangrelor reduce mortality versus oral P2Y12 in cardiogenic shock PCI? Why it is still open: The only direct comparison [8] showed a favorable but non-significant mortality difference (P=0.34 at 30 days, P=0.08 at 12 months).
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19